Evidence map›Paper›PMID 36908664›Full record

ArticleJACC. Basic to translational science2023

Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels.

Mukesh Punjabi, Alexandra Kosareva, Lifen Xu, Amanda Ochoa-Espinosa, Sarah Decembrini, Georg Hofmann, Samira Wyttenbach, Bidda Rolin, Michael Nyberg, Beat A Kaufmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Biomolecules & biomedicine · 2026
    Article
  3. GLP-1 and the cardiovascular system.The Journal of clinical investigation · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mukesh PunjabiCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Alexandra KosarevaCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Lifen XuCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Amanda Ochoa-EspinosaCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Sarah DecembriniCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Georg HofmannCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Samira WyttenbachCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.
Bidda RolinGlobal Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.
Michael NybergGlobal Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.
Beat A KaufmannCardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors determined the effect of the GLP-1 receptor agonist liraglutide on endothelial surface expression of vascular cell adhesion molecule (VCAM)-1 in murine apolipoprotein E knockout atherosclerosis. Contrast-enhanced ultrasound molecular imaging using microbubbles targeted to VCAM-1 and control microbubbles showed a 3-fold increase in endothelial surface VCAM-1 signal in vehicle-treated animals, whereas in the liraglutide-treated animals the signal ratio remained around 1 throughout the study. Liraglutide had no influence on low-density lipoprotein cholesterol or glycated hemoglobin, but reduced TNF-α, IL-1β, MCP-1, and OPN. Aortic plaque lesion area and luminal VCAM-1 expression on immunohistology were reduced under liraglutide treatment.

Indexed as

ApoE, apolipoprotein EatherosclerosisCEUMI, contrast-enhanced ultrasound molecular imagingCVD, cardiovascular diseaseGLP-1RA, glucagon-like peptide-1 receptor agonistGLP-1R, glucagon-like peptide-1 receptorGLP, glucagon-like peptideHbA1c, glycated hemoglobinHDL-C, high-density lipoprotein cholesterolICAM, intercellular cell adhesion moleculeIL, interleukinLDL-C, low-density lipoprotein cholesterolliraglutideMBCtr, control microbubblesMB, microbubbleMBVCAM-1, microbubbles targeted to VCAMMCP, monocyte chemoattractant proteinmolecular imagingOPN, osteopontinTGRL, triglyceride-rich lipoproteinsTG, triglyceridesTNF, tumor necrosis factorultrasoundVCAM, vascular cell adhesion moleculeVLDL-C, very low-density lipoprotein cholesterol

Identifiers

PMID36908664
PMCPMC9998474

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.